Skip to main content

Table 3 Risk factors by univariate and multivariate analysis

From: 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study

  Univariate analysis multivariate analysis
  p value OR(95%CI) p value OR(95%CI)
Complete Response in the overall phase
Gender:Male vs Female 0.005 1.830[1.204–2.783]   
Age: 65 vs < 65 0.090 1.438[0.945–2.187] 0.099 1.448[0.933–2.249]
Motion sickness: Yes vs No 0.003 0.422[0.241–0.740] 0.011 0.469[0.261–0.840]
Drinking habit: Yes vs No 0.032 1.578[1.040–2.394] 0.143 1.394[0.894–2.175]
Smoking History:Yes vs No 0.057 1.523[0.987–2.350]   
Pregnancy associated vomiting: Yes vs Others 0.006 0.516[0.322–0.872] 0.040 0.589[0.355–0.977]
palonosetron vs 1st generation 5HT3RA 0.723 0.927[0.608–1.412] 0.070 0.560[0.300–1.048]
CBDCA-based chemotherapy vs Others 0.469 0.858[0.567–1.299] 0.027 0.494[0.264–0.922]
Total Control in overall phase
Gender:Male vs Female 0.002 1.911[1.275–2.864]   
Age: 65 vs < 65 0.004 1.807[1.205–2.709] 0.006 1.829[1.191–2.808]
Motion sickness: Yes vs No 0.003 0.408[0.226–0.734] 0.031 0.510[0.277–0.939]
Drinking habit: Yes vs No 0.006 1.755[1.172–2.628] 0.059 1.520[0.984–2.348]
Smoking History:Yes vs No 0.194 1.313[0.871–1.979]   
Pregnancy associated vomiting: Yes vs Others < 0.001 0.375[0.230–0.611] 0.003 0.460[0.275–0.770]
palonosetron vs 1st generation 5HT3RA 0.445 1.172[0.780–1.759]   
CBDCA-based chemotherapy vs Others 0.364 0.831[0.557–1.239] 0.063 0.666[0.434–1.023]
  1. Backward selection method with an entry and exit criteria of 0.2
  2. OR Odds ratio, CI Confidence interval, 5HT3RA 5-hydroxytryptamine-3 receptor antagonist, CBDCA Carboplatin